Current filters:


Popular Filters

1900 to 1924 of 2299 results

Sunshine Act data collection delayed to January 2013, says USA's CMS


In a web site posting last week, The US Center for Medicare and Medicaid Services (CSM) announced that…

BiotechnologyNorth AmericaPharmaceuticalPoliticsRegulation

Life sciences M&A activity heats Up in April, says Burrill & Co


April proved to be a big month for M&A activity in the life sciences as companies announced more than…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

US NIH debuts collaborative program with Pharma to spur therapeutic development


The US National Institutes of Health last week unveiled a collaborative program that will match researchers…

AstraZenecaBiotechnologyEli LillyNorth AmericaPfizerPharmaceuticalResearch

GAO report finds that USA's FDA has met most PDUFA performance goals


A report dated March 30 but only released earlier this week by the US Government Accountability Office…

BiotechnologyNorth AmericaPharmaceuticalRegulation

New biologics and biosimilars approval guidelines in Mexico


In Mexico, new guidelines are now in effect for the market authorization of biologics and biosimilars,…

BiotechnologyGenericsRegulationSouth America

Genzyme gains FDA and EMA approval for Irish production plant


US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) said yesterday that…


Unmet needs in orphan diseases therapy offer opportunity for Big Pharma; report


Patients suffering from orphan diseases can look forward to a wider range of drug options in the future,…

BiotechnologyMarkets & MarketingPharmaceuticalRare diseasesResearch

Patient perspectives influencing drug development


Support is growing for increased collaboration between pharmaceutical companies and patients in research…


Biogen Idec 1st-qtr sales up 7% but fail to match expectations


US biotech company Biogen Idec (Nasdaq: BIIB) post first-quarter 2012 sales of $1.29 billion, a rise…

Biogen IdecBiotechnologyFinancial

New business model to relaunch the BioPharma industry, from ADL


Traditionally, clinical diagnoses and treatments have focused on diseases and cures. For every ailment,…

BiotechnologyManagementMarkets & MarketingPharmaceutical

Actelion's macitentan meets primary endpoint in pivotal Phase III PAH study


Europe's largest biotech company, Actelion (SIX: ATLN), says that initial analysis indicates that the…

ActelionBiotechnologymacitentanResearchRespiratory and Pulmonary

Biopharmaceuticals "no longer a growth market" in Germany


After years of consistent growth, the German biopharmaceuticals market came to a juddering halt last…

BiotechnologyEuropeMarkets & MarketingPharmaceuticalPoliticsPricingRegulation

FDA stalls Amgen's Xgeva sBLA for prevention of bone metastases


USA-based Amgen (Nasdaq: AMGN) revealed on Friday that the US Food and Drug Administration has issued…

AmgenBiotechnologyNorth AmericaOncologyRegulationXgeva

BIO asks US House Committee on Ways and Means to extend critical tax provisions; backs Obama Bioeconomy Blueprint


US trade group the Biotechnology Industry Organization (BIO) has submitted a statement for the record…

BiotechnologyFinancialNorth AmericaPolitics

Drugmakers looking to shorten time to early clinical development, says Tufts CSDD


Pharmaceutical companies looking to increase the efficiency and productivity of their R&D pipelines are…

BiotechnologyNorth AmericaPharmaceuticalResearch

Sanofi's strong 1st-qtr driven by Genzyme


French drug major Sanofi (Euronext: SAN) posted a strong set of first-quarter 2012 financial results…


Epizyme earns upfront $90 million in deal with Celgene; latter posts 17% sales hike


Privately-held Epizyme and Celgene International Sarl, a subsidiary of USA-based Celgene Corp (Nasdaq:…


Amylin operating loss leaps to over $30 million


US biotech firm Amylin Pharmaceuticals (Nasdaq AMLN): reported financial results for the quarter ended…

AmylinBiotechnologyFinancialMergers & Acquisitions

Amgen acquires Turkish drugmaker Mustafa Nevzat for $700 million


Global biotech giant Amgen (Nasdaq: AMGN) has reached agreement to acquire 95.6% of Mustafa Nevzat Pharmaceuticals…

AmgenBiotechnologyMergers & AcquisitionsMustafa Nevzat PharmaPharmaceutical

Positive Ph III data for Biogen Idec's oral MS drug candidate BG-12


US biotech firm Biogen Idec (Nasdaq: BIIB) says that detailed positive data from CONFIRM, the second…

Biogen IdecBiotechnologydimethyl fumarateNeurologicalResearch

Amgen beats forecasts as EPS leaps more than 20%


USA-based Amgen (Nasdaq: AMGN), the world's biggest independent biotech company, posted strong first-quarter…


GSK takeover target Human Genome sees 4th-qtr loss narrow


Human Genome Sciences (Nasdaq: HGSI), the subject of a $2.59 billion hostile takeover bid from the UK's…

BenlystaBiotechnologyFinancialHuman Genome Sciences

1900 to 1924 of 2299 results

Back to top